trial
as of 2026-07-01A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
NCTId NCT07230652
at a glance
Phase 1 · Recruiting
Enrollment 40 (estimated)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-08-20
Primary completion
2025-12-31
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Sites
1 total
Beijing, China
Facts & assertions
4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2025-12-31
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication